Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
about
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controllerGenome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals.HIV-1 neutralizing antibody response and viral genetic diversity characterized with next generation sequencingAn investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virusFeline immunodeficiency virus (FIV) neutralization: a reviewFunctional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal AntibodiesHIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialModest attenuation of HIV-1 Vpu alleles derived from elite controller plasmaHIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing ActivityCross-reactive broadly neutralizing antibodies: timing is everything.Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialDetection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulationsHIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.Neutralizing antibodies and control of HIV: moves and countermoves.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV.Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral BurdensHighly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies.HIV Vaccination: A Roadmap among Advancements and Concerns.
P2860
Q34132738-EC8B1B74-AE62-4D44-83F9-D1E72A13CE2CQ34182086-C9E548F8-4E79-42C1-B08C-843A639C7643Q34571277-7BB67238-7938-4892-BD1E-5EDD13BCA266Q34657046-2EB75A93-0E71-42E2-AFB6-6F6540D66765Q35109028-58A9791C-8A95-4E26-9654-85D925556DB8Q35491705-C8C5F8CD-D3F8-440A-AAE8-BCB5F96B5D05Q35540085-5A768261-0B3D-4874-AFAC-2B021EE649C7Q35552889-09B6DDF4-95DE-41F5-857E-C12019A633A0Q35582429-327AE9F7-E388-4CE1-82E9-79A599F5D36CQ35741316-08293975-2ED7-4AF6-8145-843D752AE8F5Q36105782-C8253275-7004-421E-A611-1EF2FFE49186Q36707546-167132CE-E47F-477B-B4B4-1CB3CB045540Q36986644-3A1C6F32-15C2-4463-BABB-E24D870A8919Q37069837-37DAC2D6-6844-414D-9972-12491FCEBCFBQ37254327-68FA2164-8DD2-471E-93E2-C2D5E049F297Q37484124-24B3C85F-0604-4238-8B80-D7477961F658Q37971867-EE26BAED-997E-4231-8B94-504FC404DE5FQ38415577-55BD83D5-91F1-4C37-BBCC-E8A17D861B1AQ38533881-C06A9A83-517A-4A24-8AA4-2AC40D5999B0Q39108760-98320021-C1A7-4235-8AA2-B472176F003AQ40346802-E3ABA4B0-DBD4-492B-924C-AD7AD2395C4DQ40695938-9C32F479-604D-4898-9E37-50844727FD43Q42228026-20D6B0A1-A29D-4A68-9B2D-B109B471EF8CQ47548101-607FC9D1-0D15-4542-A4D2-3ABD78AF6A5AQ53825583-6923C766-8410-4762-811C-8DD662E0788AQ54207383-F1F80B02-8A49-45F2-AA44-0BCB5583F589Q54232567-55245653-93F9-41F1-B4D5-D0DF9FC85FB0
P2860
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
@ast
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
@en
type
label
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
@ast
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
@en
prefLabel
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
@ast
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
@en
P2093
P2860
P356
P1433
P1476
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia
@en
P2093
A Merino-Mansilla
C B Ferreira
J M Alcocer-González
J M Gatell
M Medina-Ramírez
P2860
P304
P356
10.1128/JVI.02482-10
P407
P577
2011-04-06T00:00:00Z